 |
|
|
| |
Efficacy and safety of MK-5172 + MK-8742± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hCV gT1 infection: The C-WORTHY study (Final results, Parts A and B)
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Mark S. Sulkowski, Christophe Hezode, Jan Gerstoft, John M. Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo,
Nina Weis, Ronald Nahass, Oren Shibolet, Lawrence Serfaty, Marc Bourlière, Edwin DeJesus, Eli Zuckerman, Frank Dutko, Anita Y. M.Howe, Melissa Shaughnessy, Peggy Hwang, Janice
Wahl, Michael Robertson, Eliav Barr, Barbara Haber
|
| |
|
|
|
|
|
